Related Experiment Videos
Clinical experience with BCG alone versus BCG plus epirubicin
Summary
This study found that alternating Bacillus Calmette-Guérin (BCG) and epirubicin did not improve efficacy for superficial bladder cancer and increased side-effects. Combination therapy is not recommended for high-risk patients.
Area of Science:
- Oncology
- Urology
- Cancer Research
Background:
- Superficial bladder cancer treatment often involves Bacillus Calmette-Guérin (BCG) and epirubicin.
- High-risk superficial bladder tumors require effective therapeutic strategies.
Purpose of the Study:
- To evaluate if alternating BCG and epirubicin improves efficacy and tolerability for high-risk superficial bladder cancer.
- To compare recurrence rates, progression, and side-effects between combination therapy and BCG alone.
Main Methods:
- A randomized study involving 41 patients with high-risk superficial bladder transitional carcinoma.
- Patients received either BCG alone or sequential BCG and epirubicin.
- Follow-up duration ranged from 9-24 months (mean 18 months).
Main Results:
- Tumor recurrence rates were 15% for BCG/epirubicin and 19% for BCG alone.
- Progression rates were 4.7% for BCG/epirubicin and 10% for BCG alone.
- Serious side-effects requiring antituberculosis treatment occurred in three patients receiving combination therapy.
Conclusions:
- Alternating BCG and epirubicin did not demonstrate superior efficacy compared to standard BCG treatment for superficial bladder cancer.
- The combination therapy was associated with a higher incidence of serious side-effects.
- This study does not recommend the combination of BCG and epirubicin for high-risk superficial bladder cancer patients.